LINE

    Text:AAAPrint
    Society

    Guideline speeds access to drugs

    1
    2017-10-10 10:41China Daily Editor: Wang Zihao ECNS App Download

    Drugs developed in other countries are expected to be available for use on the Chinese mainland more quickly under a new guideline released by the central government.

    Authorities in China will now accept data collected from clinical trials conducted outside the mainland for applications to register drugs and medical equipment, according to the guideline on reforming approval procedures, which was released by the State Council on Sunday.

    The data must be collected from clinical trials conducted at more than one center and must meet Chinese regulations for registration of drugs and medical equipment, the guideline said.

    "The purpose of the measure is to reduce the time needed for approval of drugs from overseas," Wu Zhen, vice-minister of the China Food and Drug Administration, said on Monday.

    China's current drug evaluation and approval system needs improving to expedite the use of new drugs in China, Wu said.

    Under current regulations, food and drug authorities cannot accept clinical trial data collected from overseas, and new drugs being developed overseas should finish their first phase of clinical trials overseas before developers can apply to start clinical trials on the mainland, he said.

    This has delayed the availability of some major drugs on the Chinese market, he said.

    Of 433 drugs approved for sale in developed countries between 2001 and last year, only 30 percent are available on the Chinese mainland.

    Over the past 10 years, patients on the mainland have had to wait five to seven years longer for some major new drugs than patients in Europe and the United States, he said.

    "This has caused an increasing number of people to buy drugs through the internet and from overseas, which has many potential risks," he said.

    "Recognizing data collected from overseas can reduce unnecessary trials, which reduces the cost of drug research and development and improves Chinese patients' access to drugs," said Wang Lifeng, chief of product registration for drugs and cosmetics at the CFDA.

    The CFDA will make more detailed regulations to better carry out the guideline, he said.

    Meanwhile, the administration will intensify its supervision and inspection of clinical trials conducted overseas, and send inspectors to clinical trial centers overseas for site inspection to ensure that the data collected are accurate, Wang said.

    The guideline also bans medical representatives from selling drugs and will hold them accountable if they have done so.

      

    Related news

    MorePhoto

    Most popular in 24h

    MoreTop news

    MoreVideo

    News
    Politics
    Business
    Society
    Culture
    Military
    Sci-tech
    Entertainment
    Sports
    Odd
    Features
    Biz
    Economy
    Travel
    Travel News
    Travel Types
    Events
    Food
    Hotel
    Bar & Club
    Architecture
    Gallery
    Photo
    CNS Photo
    Video
    Video
    Learning Chinese
    Learn About China
    Social Chinese
    Business Chinese
    Buzz Words
    Bilingual
    Resources
    ECNS Wire
    Special Coverage
    Infographics
    Voices
    LINE
    Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
    Copyright ©1999-2018 Chinanews.com. All rights reserved.
    Reproduction in whole or in part without permission is prohibited.
    主站蜘蛛池模板: 洛宁县| 武夷山市| 明星| 齐河县| 湄潭县| 水富县| 大冶市| 巍山| 剑川县| 通河县| 嘉鱼县| 壤塘县| 延川县| 西安市| 泗洪县| 北辰区| 孝义市| 五常市| 湟中县| 普安县| 宝兴县| 永顺县| 克东县| 巫山县| 无棣县| 即墨市| 锡林郭勒盟| 武功县| 武邑县| 龙陵县| 佳木斯市| 德阳市| 建宁县| 黔南| 平江县| 龙里县| 清原| 江西省| 全椒县| 剑川县| 阳春市|